US · CLNNW
Clene Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Salt Lake City, UT 84121
- Website
- clene.com
Price · as of 2024-12-31
—
Market cap 11.22M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $212.98 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $117.00 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $0.00 | $212.98 |
AI valuation
Our deep-learning model estimates Clene Inc.'s (CLNNW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
$212.98
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CLNNW | Clene Inc. | $0.01 | 11.22M | — | — | — | +2,366,356% | — | — | — | — | — | — | 79.53% | -9676.32% | -11520.47% | -1738.36% | -637.51% | -98.90% | -2.35 | -8.14 | 1.57 | 1.22 | -0.26 | -3987.00% | -4771.00% | -3003.00% | — | -2.07 | -411.12% | — | 0.00% | — | — | — | — | — |
| ABP | Abpro Corporation | $5.55 | 11.25M | +805% | +295% | — | — | -0.66 | -0.31 | 26.19 | -0.85 | — | -0.30 | 100.00% | -5421.31% | -3951.91% | 14.30% | 20.14% | -180.44% | -0.21 | -25.64 | 0.19 | 0.16 | -0.08 | -3840.00% | 5000.00% | 2121.00% | -188.40% | -0.46 | 18.33% | 0.00% | 0.00% | 35.32% | -0.53 | -0.58 | 28.80 | -45.79 |
| APM | Aptorum Group Limited | $1.40 | 10M | +17,123% | — | — | — | -1.20 | 0.24 | — | -2.03 | -4.65 | 0.24 | 0.00% | — | — | -18.56% | -15.20% | -23.21% | 0.16 | -25.84 | 0.22 | 0.20 | -0.66 | 2581.00% | -10000.00% | -8459.00% | -23.24% | -0.27 | -4.77% | 0.00% | 0.00% | 0.00% | -2.00 | -6.39 | — | -6.61 |
| BOLT | Bolt Biotherapeutics, Inc… | $4.87 | 9.33M | +409% | -28% | — | — | -5.28 | 5.82 | 43.30 | -4.68 | — | 5.82 | 100.00% | -949.91% | -820.78% | -74.28% | -221.84% | -48.66% | 0.44 | — | 3.20 | 3.06 | -0.27 | -984.00% | -236.00% | -1205.00% | -18.42% | -3.87 | -186.26% | 0.00% | 0.00% | 0.00% | -4.26 | -5.07 | 40.42 | -3.22 |
| CING | Cingulate Inc. | $3.82 | 20.68M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CLRB | Cellectar Biosciences, In… | $3.34 | 10.66M | — | — | — | — | -0.26 | 0.82 | — | 0.22 | — | 0.82 | 0.00% | — | — | -17221.69% | 330.97% | -237.45% | 0.03 | — | 2.58 | 2.48 | 0.44 | -6010.00% | — | 4346.00% | -406.92% | -5.07 | 304.82% | 0.00% | 0.00% | 117.61% | 0.21 | 0.23 | — | -18.97 |
| MBIO | Mustang Bio, Inc. | $1.32 | 9.56M | — | — | — | — | -0.58 | -2.34 | — | -0.21 | — | -2.34 | 0.00% | — | — | 840.11% | 241.62% | -116.47% | -0.23 | 3249.00 | 0.68 | 0.57 | 0.40 | -5717.00% | — | -7699.00% | -125.80% | -0.90 | 169.70% | 6.74% | -3.90% | 31.27% | -0.19 | -0.27 | — | -65.53 |
| MRKR | Marker Therapeutics, Inc. | $0.92 | 9.9M | +5,273% | +58% | — | — | -1.26 | 0.73 | 2.04 | 0.51 | — | 0.73 | -104.33% | -168.69% | -162.82% | -65.81% | 1313.50% | -54.82% | 0.00 | — | 6.36 | 6.22 | 1.73 | -3834.00% | 9906.00% | -3364.00% | -81.00% | -3.15 | 1288.92% | 0.00% | 0.00% | 30.30% | 0.51 | 0.52 | -0.87 | -26.44 |
| OSRH | OSR Holdings, Inc. | $0.59 | 12.78M | — | — | — | — | -5.08 | -1.58 | — | -3.39 | — | -1.58 | 0.00% | — | — | -15.54% | -21.87% | -10.39% | -0.27 | 81.95 | 0.07 | 0.01 | -0.48 | -85209.00% | — | 16722.00% | -21.32% | -0.33 | -15.79% | 0.00% | 0.00% | 0.00% | -3.39 | -5.47 | — | -12.68 |
| TVGN | Tevogen Bio Holdings Inc. | $0.53 | 103.27M | — | — | — | — | -12.18 | -25.05 | — | -12.85 | -0.05 | -25.05 | 0.00% | — | — | 27.16% | 2087.12% | -306.17% | -0.43 | -291.05 | 0.26 | 0.16 | -0.12 | 2330000.00% | — | 4449.00% | -7.18% | -1.33 | 467.53% | 0.00% | 0.00% | 55.48% | -3.15 | -14.07 | — | -89.34 |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
- CEO
- Robert Etherington MBA
- Employees
- 75
- Beta
- 0.77
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).